Ikena Oncology (IKNA)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	46.06 mm	46.06 mm	46.06 mm	46.06 mm	46.06 mm	46.06 mm
Cash burn (monthly)	(no burn)	6.37 mm	4.14 mm	5.70 mm	2.98 mm	5.13 mm
Cash used (since last report)	n/a	26.95 mm	17.48 mm	24.08 mm	12.59 mm	21.69 mm
Cash remaining	n/a	19.12 mm	28.58 mm	21.98 mm	33.47 mm	24.37 mm
Runway (months of cash)	n/a	3.0	6.9	3.9	11.2	4.8

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

IKNA institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	62	74	-16.2%
Opened positions	7	29	-75.9%
Closed positions	19	15	+26.7%
Increased positions	12	14	-14.3%
Reduced positions	19	18	+5.6%

13F shares	Current	Prev Q	Change
Total value	47.94 bn	46.99 bn	+2.0%
Total shares	43.39 mm	43.99 mm	-1.4%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Atlas Venture Life Science Advisors	5.02 mm	$8.68 bn	0.0%
Biotechnology Value Fund L P	4.77 mm	$0.00	0.0%
BVF	4.77 mm	$8.25 bn	0.0%
Blue Owl Capital	4.09 mm	$7.08 bn	0.0%
Orbimed Advisors	3.54 mm	$6.12 bn	0.0%
GILD Gilead Sciences	2.93 mm	$12.28 mm	0.0%
Atlas Venture Fund X	2.90 mm	$74.28 mm	0.0%
Omega Fund Management	2.25 mm	$3.89 bn	0.0%
Omega Fund VI	2.25 mm	$3.04 mm	0.0%
BMY Bristol-Myers Squibb	2.13 mm	$3.63 mm	0.0%

Largest transactions	Shares	Bought/sold	Change
BLK BlackRock	0.00	-354.84 k	EXIT
BlackRock	352.18 k	+352.18 k	NEW
FNY Investment Advisers	231.38 k	+231.38 k	NEW
GS The Goldman Sachs Group, Inc.	58.62 k	-215.21 k	-78.6%
NTRS Northern Trust	48.11 k	-168.74 k	-77.8%
BML Capital Management	723.29 k	+138.17 k	+23.6%
Verition Fund Management	0.00	-135.30 k	EXIT
Vazirani Asset Management	115.67 k	+115.67 k	NEW
BBR Partners	130.00 k	+110.00 k	+550.0%
Millennium Management	249.42 k	-105.29 k	-29.7%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

IKNA insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
7 Jun 24	Owen Hughes	Stock Option Common Stock	Grant	Acquire A	No	No	1.75	17,520	30.66 k	17,520
7 Jun 24	Maria Koehler	Stock Option Common Stock	Grant	Acquire A	No	No	1.75	17,520	30.66 k	17,520
7 Jun 24	Stampacchia Otello	Stock Option Common Stock	Grant	Acquire A	No	No	1.75	17,520	30.66 k	17,520
7 Jun 24	Formela Jean Francois	Stock Option Common Stock	Grant	Acquire A	No	No	1.75	17,520	30.66 k	17,520
7 Jun 24	Richard Wooster	Stock Option Common Stock	Grant	Acquire A	No	No	1.75	17,520	30.66 k	17,520

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

12 Health Care Stocks Moving In Monday's Pre-Market Session

23 Dec 24

Ikena And Inmagene Enter Merger Agreement; $175M To Support IMG-007 Development, Includes $75M Private Placement; Combined Company ImageneBio To Target Atopic Dermatitis; Expected Close Mid-2025 And Trade On Nasdaq Under The Ticker "IMA"

23 Dec 24

Inmagene Biopharmaceuticals is a clinical stage company focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody with an extended half-life and a silenced ADCC functionThe transaction is expected to

HC Wainwright & Co. Reiterates Buy on Ikena Oncology, Maintains $4 Price Target

11 Nov 24

HC Wainwright & Co. analyst Andres Maldonado reiterates Ikena Oncology (NASDAQ:IKNA) with a Buy and maintains $4 price target.

Press releases

From Benzinga Pro

Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement

23 Dec 24